MELBOURNE, Australia , INDIANAPOLIS and LAKE MARY, Fla. , Sept. 23, 2024 /PRNewswire/ -- Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) and RLS ( USA ) Inc.
(RLS, RLS Radiopharmacies), America's only Joint Commission-accredited radiopharmacy network distributing PET [1] , SPECT [2] and therapeutic radiopharmaceuticals, today announced an agreement by the Company to acquire RLS from its parent company, RLS Group Ltd. The acquisition significantly expands Telix's North American manufacturing footprint and establishes the basis of a next generation radiometal production network to benefit Telix and select strategic commercial partners. Strategic Rationale The acquisition of RLS is aligned to Telix's investment strategy around vertically integrated supply chain, manufacturing, and distribution, further enabling the delivery of future clinical and commercial radiopharmaceutical products.
The Company views this as a necessary measure to ensure product integrity and delivery, and to strengthen and complement existing commercial partnerships. Telix will leverage RLS' 31 licensed radiopharmacies located in major metropolitan areas across the U.S.
to build a radiometal production and distribution network for key therapeutic and diagnostic isotopes alongside last-mile delivery of finished unit doses in relevant markets. The RLS footprint includes over 100,000 square ft of appropriately licensed expansion space that can be utilised to meet rapidly growing production demand..